scholarly journals Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching

2022 ◽  
Vol 15 (1) ◽  
pp. 95
Author(s):  
Giovanni Damiani ◽  
Giulia Odorici ◽  
Alessia Pacifico ◽  
Aldo Morrone ◽  
Rosalynn R. Z. Conic ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Rescue Therapy ◽  
Therapeutic Option ◽  
Real Life ◽  
Chronic Inflammatory Disease ◽  
Life Study ◽  
Secondary Failure ◽  
The Moment ◽  
Effective Drugs

Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug failure also with very effective drugs (i.e., secukinumab) and, consequently, dermatologists have two therapeutic options: switching or perform a combination therapy (rescue therapy) to save the drug that had decreased its efficacy. At the moment no studies focused on combination/rescue therapy of secukinumab, so we performed a 52-weeks multicenter retrospective observational study that involved 40 subjects with plaque psoriasis that experienced a secondary failure and were treated with combination therapy (ciclosporin (n = 11), MTX (n = 15), NB-UVB (n = 7) and apremilast (n = 7)). After 16 weeks of rescue/combination therapy, PASI and a DLQI varied respectively from 8 [7.0–9.0] and 13 [12.0–15.0], to 3 [2.8–4.0] and 3 [2.0–3.3]), suggesting a significant improvement of daily functionality and quality of life. Results were maintained at 52 weeks. No side effects were experienced during the study. Secukinumab remains a safety and effective drug for PsO patients also in the IL-23 and JAK inhibitors era. The rescue therapy is a valid therapeutic option in case of secukinumab secondary failure.

scholarly journals Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data

2018 ◽  
Vol 10 (2) ◽  
Author(s):  
Aikaterini Kyriakou ◽  
Anastasia Trigoni ◽  
Nikiforos Galanis ◽  
Dimitrios Sotiriadis ◽  
Aikaterini Patsatsi
Keyword(s):  
Quality Of Life ◽  
Hidradenitis Suppurativa ◽  
Therapeutic Potential ◽  
Therapeutic Option ◽  
Real Life ◽  
Life Quality ◽  
Global Assessment Scale ◽  
Friedman's Test ◽  
Adalimumab Treatment

Hidradenitis suppurativa (HS) is a relapsing, inflammatory disease characterized by painful nodules, abscesses, sinuses track formation and scarring. HS has a great impact on patients’ quality of life and its treatment may be really challenging. Adalimumab provides a new therapeutic option for HS. Our aim was to assess the therapeutic potential of adalimumab on patients with HS based on the data from the daily clinical practice of an HS Outpatient Clinic. 19 patients with clinically evident moderate to severe HS, under adalimumab treatment for at least 24 week, participated in this observational, retrospective study. The Hidradenitis Suppurativa Physician’s Global Assessment scale, Modified Santorius scale and Dermatology Life Quality Index (DLQI) at baseline, week 4, week 12 and week 24 were retrieved from the records. Both Modified Santorius score and DLQI were significantly decreased during the weeks of evaluation (Friedman’s test; P < 0.001). The proportion of patients who achieved clinical response was 10.5% (n = 2) at week 4, 42.1% (n = 8) at week 12 and 63.2% (n = 12) at week 24. Treatment with adalimumab was linked with both clinical remission of HS and improvement of patients’ quality of life.

scholarly journals Quality of life in asthmatic children and their caregivers after two-year treatment with omalizumab, a real-life study

2017 ◽  
Vol 5 ◽  
pp. 439-447 ◽  
Author(s):  
Anna Sztafińska ◽  
Joanna Jerzyńska ◽  
Włodzimierz Stelmach ◽  
Katarzyna Woicka-Kolejwa ◽  
Iwona Stelmach
Keyword(s):  
Quality Of Life ◽  
Real Life ◽  
Life Study ◽  
Asthmatic Children ◽  
Real Life Study

scholarly journals An Observational Real-Life Study with a New Infant Formula in Infants with Functional Gastro-Intestinal Disorders

Nutrients ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 3336
Author(s):  
Yvan Vandenplas ◽  
Laetitia Gerlier ◽  
Karin Caekelbergh ◽  
Mike Possner ◽  
Keyword(s):  
Quality Of Life ◽  
Lactobacillus Reuteri ◽  
Real Life ◽  
Magnesium Content ◽  
Nutritional Intervention ◽  
Cow Milk ◽  
Life Study ◽  
Real Life Study ◽  
Life Circumstances

Functional gastro-intestinal disorders (FGIDs) impair the quality of life of many infants and their families. A formula with partial whey hydrolysate, starch, high magnesium content, prebiotic fructo-oligosaccharide and galacto-oligosaccharide and the probiotic Lactobacillus reuteri DSM 17938 was given during two weeks to 196 infants with at least two FGIDs. The efficacy was evaluated with the Cow Milk-associated Symptom Score (CoMiSS®) and quality of life with the QUALIN score. The formula was shown to decrease FGIDs within three days (decrease of CoMiSS −1.29 (3.15) (mean (SD), p < 0.0001) followed by an improvement of quality of life after seven days (increase QUALIN +1.4 (7.8); p: 0.008). Constipation decreased from 18.8% to 6.5% within three days. In combination with reassurance and guidance, the nutritional intervention was shown to be effective in infants with FGIDS in real-life circumstances.

scholarly journals Effects of herbal medicine on acute cough and quality of life in children and their parents - A prospective real life study

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Baljosevic I ◽  
Bajec-Opancina A ◽  
Subarevic V ◽  
Stankovic K ◽  
Novkovic M ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Herbal Medicine ◽  
Real Life ◽  
Acute Cough ◽  
Life Study ◽  
Real Life Study

Initial combination therapy with vildagliptin plus metformin in drug-naïve patients with T2DM: a 24-week real-life study from Asia

2018 ◽  
Vol 34 (9) ◽  
pp. 1605-1611 ◽  
Author(s):  
Manoj Chawla ◽  
Tae Ho Kim ◽  
Roberto C. Mirasol ◽  
Pathan Faruque ◽  
Kathryn Cooke ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Real Life ◽  
Life Study ◽  
Initial Combination Therapy ◽  
Drug Naïve ◽  
Real Life Study ◽  
Initial Combination

The relationship between asthma control and quality-of-life impairment due to chronic cough: a real-life study

2008 ◽  
Vol 101 (4) ◽  
pp. 370-374 ◽  
Author(s):  
Fulvio Braido ◽  
Ilaria Baiardini ◽  
Sara Balestracci ◽  
Omar Fassio ◽  
Silvia Ravera ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Asthma Control ◽  
Chronic Cough ◽  
Real Life ◽  
Life Study ◽  
Real Life Study ◽  
The Relationship

scholarly journals Azathioprine and Infliximab: Monotherapy or Combination Therapy in the Treatment of Crohn's Disease

2011 ◽  
Vol 4 ◽  
pp. CGast.S5256 ◽  
Author(s):  
Bryan L. Love ◽  
Lisa S. Smith ◽  
Steedman A. Sarbah ◽  
Fred C. Fowler
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Combination Therapy ◽  
Tumor Necrosis ◽  
Chronic Inflammatory Disease ◽  
First Line ◽  
Tnf Antagonists ◽  
Systemic Corticosteroids ◽  
Necrosis Factor

Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract often resulting in complications resulting in decreased quality of life. Several classes of medications are available to clinicians including mesalamine, budesonide, systemic corticosteroids, thiopurine derivatives, and monoclonal antibodies which target tumor necrosis factor (TNF). Guidelines generally recommend reserving TNF-antagonists for patients who have failed other first-line therapies; however, emerging data suggests there may be some benefit in combining TNF-antagonists, specifically infliximab, with azathioprine. The purpose of this review is to compare the benefits and risks of combination therapy, and identify patients who may benefit most from this approach.

Sign in / Sign up

Export Citation Format

Share Document